BioLife Solutions, Inc. Logo

BioLife Solutions, Inc.

BLFS

(1.8)
Stock Price

25,72 USD

-62.21% ROA

-192.23% ROE

-7.28x PER

Market Cap.

769.411.300,00 USD

13.31% DER

0% Yield

-46.37% NPM

BioLife Solutions, Inc. Stock Analysis

BioLife Solutions, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioLife Solutions, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (89.76%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-2.05x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-16%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROA

The stock's ROA (-46.34%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-71) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

BioLife Solutions, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioLife Solutions, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

BioLife Solutions, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioLife Solutions, Inc. Revenue
Year Revenue Growth
1989 100.000
1990 100.000 0%
1991 100.000 0%
1992 100.000 0%
1993 5.900.000 98.31%
1994 13.400.000 55.97%
1995 13.594.186 1.43%
1996 0 0%
1997 3.571.386 100%
1998 2.369.748 -50.71%
1999 1.776.553 -33.39%
2000 1.189.505 -49.35%
2001 1.344.016 11.5%
2002 848.791 -58.34%
2003 605.511 -40.18%
2004 626.709 3.38%
2005 614.718 -1.95%
2006 603.219 -1.91%
2007 972.262 37.96%
2008 1.322.497 26.48%
2009 1.581.600 16.38%
2010 2.081.565 24.02%
2011 2.758.729 24.55%
2012 5.662.990 51.28%
2013 8.949.401 36.72%
2014 6.190.698 -44.56%
2015 6.448.910 4%
2016 8.227.000 21.61%
2017 11.022.000 25.36%
2018 19.742.000 44.17%
2019 27.371.000 27.87%
2020 48.087.000 43.08%
2021 119.156.000 59.64%
2022 161.759.000 26.34%
2023 133.312.000 -21.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioLife Solutions, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 2.899.686 100%
1996 0 0%
1997 1.293.470 100%
1998 674.160 -91.86%
1999 687.450 1.93%
2000 1.373.500 49.95%
2001 1.773.119 22.54%
2002 644.798 -174.99%
2003 759.309 15.08%
2004 29.087 -2510.48%
2005 27.855 -4.42%
2006 57.330 51.41%
2007 413.376 86.13%
2008 457.640 9.67%
2009 414.465 -10.42%
2010 318.897 -29.97%
2011 516.454 38.25%
2012 463.638 -11.39%
2013 487.816 4.96%
2014 871.100 44%
2015 1.378.807 36.82%
2016 2.029.000 32.04%
2017 1.193.000 -70.08%
2018 1.298.000 8.09%
2019 4.120.000 68.5%
2020 6.720.000 38.69%
2021 11.819.000 43.14%
2022 14.798.000 20.13%
2023 21.608.000 31.52%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioLife Solutions, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 1.410.417.000 100%
2007 1.902.126.000 25.85%
2008 2.185.341 -86940.24%
2009 1.888.757 -15.7%
2010 1.500.680 -25.86%
2011 1.829.307 17.96%
2012 2.151.817 14.99%
2013 2.718.977 20.86%
2014 3.970.254 31.52%
2015 4.868.801 18.46%
2016 4.592.000 -6.03%
2017 4.523.000 -1.53%
2018 5.950.000 23.98%
2019 9.078.000 34.46%
2020 14.607.000 37.85%
2021 34.097.000 57.16%
2022 47.670.000 28.47%
2023 50.052.000 4.76%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioLife Solutions, Inc. EBITDA
Year EBITDA Growth
1989 -300.000
1990 -1.700.000 82.35%
1991 -2.700.000 37.04%
1992 -5.000.000 46%
1993 -6.900.000 27.54%
1994 -2.400.000 -187.5%
1995 -1.385.728 -73.19%
1996 0 0%
1997 -1.236.012 100%
1998 -901.235 -37.15%
1999 -830.354 -8.54%
2000 -2.603.826 68.11%
2001 -4.100.707 36.5%
2002 -451.231 -808.78%
2003 -1.563.412 71.14%
2004 -497.620 -214.18%
2005 -564.600 11.86%
2006 -1.847.710 69.44%
2007 -2.447.621 24.51%
2008 -2.400.918 -1.95%
2009 -2.192.606 -9.5%
2010 -1.320.829 -66%
2011 -1.112.522 -18.72%
2012 -756.880 -46.99%
2013 -94.869 -697.82%
2014 -3.135.690 96.97%
2015 -5.017.129 37.5%
2016 -2.065.000 -142.96%
2017 -1.056.000 -95.55%
2018 3.662.000 128.84%
2019 1.016.000 -260.43%
2020 -2.976.000 134.14%
2021 -23.983.000 87.59%
2022 -29.513.000 18.74%
2023 -45.436.000 35.04%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioLife Solutions, Inc. Gross Profit
Year Gross Profit Growth
1989 -100.000
1990 -700.000 85.71%
1991 -1.100.000 36.36%
1992 -2.600.000 57.69%
1993 1.200.000 316.67%
1994 6.600.000 81.82%
1995 7.832.188 15.73%
1996 0 0%
1997 1.652.784 100%
1998 1.093.607 -51.13%
1999 1.095.829 0.2%
2000 920.548 -19.04%
2001 555.317 -65.77%
2002 848.791 34.58%
2003 605.511 -40.18%
2004 462.730 -30.86%
2005 364.640 -26.9%
2006 305.154 -19.49%
2007 509.156 40.07%
2008 551.851 7.74%
2009 574.578 3.96%
2010 856.388 32.91%
2011 1.403.158 38.97%
2012 2.292.419 38.79%
2013 3.762.887 39.08%
2014 3.035.410 -23.97%
2015 3.814.210 20.42%
2016 4.779.000 20.19%
2017 6.746.000 29.16%
2018 13.525.000 50.12%
2019 18.513.000 26.94%
2020 27.441.000 32.54%
2021 37.748.000 27.3%
2022 53.822.000 29.87%
2023 46.596.000 -15.51%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioLife Solutions, Inc. Net Profit
Year Net Profit Growth
1989 -500.000
1990 -1.700.000 70.59%
1991 -2.600.000 34.62%
1992 -4.700.000 44.68%
1993 -6.600.000 28.79%
1994 -2.600.000 -153.85%
1995 -2.230.725 -16.55%
1996 0 0%
1997 -1.589.993 100%
1998 -1.268.341 -25.36%
1999 -1.175.722 -7.88%
2000 -2.771.927 57.58%
2001 -4.410.257 37.15%
2002 215.876 2142.96%
2003 -1.303.368 116.56%
2004 -743.162 -75.38%
2005 -619.323 -20%
2006 -1.134.018 45.39%
2007 -2.851.774 60.23%
2008 -2.775.117 -2.76%
2009 -2.768.352 -0.24%
2010 -1.983.630 -39.56%
2011 -1.956.639 -1.38%
2012 -1.659.586 -17.9%
2013 -1.084.160 -53.08%
2014 -3.217.750 66.31%
2015 -4.213.936 23.64%
2016 -6.875.000 38.71%
2017 -2.515.000 -173.36%
2018 3.266.000 177.01%
2019 11.062.000 70.48%
2020 2.667.000 -314.77%
2021 -8.383.000 131.81%
2022 -139.805.000 94%
2023 -116.528.000 -19.98%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioLife Solutions, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1989 0
1990 -1 0%
1991 -1 100%
1992 -3 50%
1993 -4 33.33%
1994 -1 -200%
1995 -1 0%
1996 0 0%
1997 -1 0%
1998 -1 0%
1999 0 0%
2000 -4 100%
2001 -5 25%
2002 0 0%
2003 -1 100%
2004 -1 0%
2005 -1 0%
2006 0 0%
2007 -1 0%
2008 -1 0%
2009 -1 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 -1 0%
2017 0 0%
2018 0 0%
2019 1 0%
2020 0 0%
2021 0 0%
2022 -3 100%
2023 -3 -50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioLife Solutions, Inc. Free Cashflow
Year Free Cashflow Growth
1990 -1.300.000
1991 -2.600.000 50%
1992 -4.700.000 44.68%
1993 -9.300.000 49.46%
1994 -2.800.000 -232.14%
1995 -1.859.480 -50.58%
1996 -2.133.504 12.84%
1997 -1.850.210 -15.31%
1998 -220.501 -739.09%
1999 -266.258 17.19%
2000 -3.084.375 91.37%
2001 -2.922.032 -5.56%
2002 -2.764.811 -5.69%
2003 -865.447 -219.47%
2004 449.304 292.62%
2005 -591.441 175.97%
2006 -747.751 20.9%
2007 -2.814.525 73.43%
2008 -2.160.106 -30.3%
2009 -2.787.173 22.5%
2010 -1.280.940 -117.59%
2011 -1.083.447 -18.23%
2012 -296.786 -265.06%
2013 -90.663 -227.35%
2014 -3.751.996 97.58%
2015 -6.391.558 41.3%
2016 -5.584.208 -14.46%
2017 461.233 1310.71%
2018 1.848.000 75.04%
2019 538.000 -243.49%
2020 1.882.000 71.41%
2021 -13.221.000 114.23%
2022 -18.874.000 29.95%
2023 -5.875.000 -221.26%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioLife Solutions, Inc. Operating Cashflow
Year Operating Cashflow Growth
1990 -1.300.000
1991 -2.500.000 48%
1992 -4.300.000 41.86%
1993 -8.400.000 48.81%
1994 -2.600.000 -223.08%
1995 -1.542.240 -68.59%
1996 -2.073.057 25.61%
1997 -1.494.917 -38.67%
1998 29.118 5234%
1999 -266.258 110.94%
2000 -2.898.632 90.81%
2001 -2.642.706 -9.68%
2002 -2.677.424 1.3%
2003 -854.228 -213.43%
2004 515.104 265.84%
2005 -576.333 189.38%
2006 -712.196 19.08%
2007 -2.708.979 73.71%
2008 -2.113.418 -28.18%
2009 -2.413.642 12.44%
2010 -1.252.526 -92.7%
2011 -989.917 -26.53%
2012 854.934 215.79%
2013 146.007 -485.54%
2014 -3.162.316 104.62%
2015 -4.973.861 36.42%
2016 -4.327.000 -14.95%
2017 605.000 815.21%
2018 2.348.000 74.23%
2019 1.213.000 -93.57%
2020 6.515.000 81.38%
2021 -4.836.000 234.72%
2022 -8.489.000 43.03%
2023 -4.379.000 -93.86%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioLife Solutions, Inc. Capital Expenditure
Year Capital Expenditure Growth
1990 0
1991 100.000 100%
1992 400.000 75%
1993 900.000 55.56%
1994 200.000 -350%
1995 317.240 36.96%
1996 60.447 -424.82%
1997 355.293 82.99%
1998 249.619 -42.33%
1999 0 0%
2000 185.743 100%
2001 279.326 33.5%
2002 87.387 -219.64%
2003 11.219 -678.92%
2004 65.800 82.95%
2005 15.108 -335.53%
2006 35.555 57.51%
2007 105.546 66.31%
2008 46.688 -126.07%
2009 373.531 87.5%
2010 28.414 -1214.6%
2011 93.530 69.62%
2012 1.151.720 91.88%
2013 236.670 -386.64%
2014 589.680 59.86%
2015 1.417.697 58.41%
2016 1.257.208 -12.77%
2017 143.767 -774.48%
2018 500.000 71.25%
2019 675.000 25.93%
2020 4.633.000 85.43%
2021 8.385.000 44.75%
2022 10.385.000 19.26%
2023 1.496.000 -594.18%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioLife Solutions, Inc. Equity
Year Equity Growth
1989 100.000
1990 3.300.000 96.97%
1991 5.500.000 40%
1992 12.000.000 54.17%
1993 5.600.000 -114.29%
1994 5.300.000 -5.66%
1995 3.981.925 -33.1%
1996 3.994.283 0.31%
1997 2.460.455 -62.34%
1998 1.431.639 -71.86%
1999 818.397 -74.93%
2000 3.628.554 77.45%
2001 310.766 -1067.62%
2002 -554.251 156.07%
2003 1.356.121 140.87%
2004 612.959 -121.24%
2005 38.481 -1492.89%
2006 180.090 78.63%
2007 -2.469.790 107.29%
2008 -5.171.113 52.24%
2009 -7.826.982 33.93%
2010 -9.548.912 18.03%
2011 -11.180.486 14.59%
2012 -12.486.023 10.46%
2013 -13.271.521 5.92%
2014 13.936.317 195.23%
2015 8.508.471 -63.79%
2016 3.166.000 -168.75%
2017 10.092.000 68.63%
2018 43.148.000 76.61%
2019 83.026.000 48.03%
2020 205.246.000 59.55%
2021 480.751.000 57.31%
2022 -246.915.000 294.7%
2023 332.017.000 174.37%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioLife Solutions, Inc. Assets
Year Assets Growth
1989 500.000
1990 3.500.000 85.71%
1991 5.600.000 37.5%
1992 13.000.000 56.92%
1993 8.400.000 -54.76%
1994 9.100.000 7.69%
1995 8.402.903 -8.3%
1996 6.044.744 -39.01%
1997 3.879.067 -55.83%
1998 2.727.482 -42.22%
1999 2.159.115 -26.32%
2000 3.988.819 45.87%
2001 1.776.590 -124.52%
2002 313.846 -466.07%
2003 2.963.911 89.41%
2004 833.269 -255.7%
2005 447.105 -86.37%
2006 560.432 20.22%
2007 726.018 22.81%
2008 1.170.622 37.98%
2009 1.333.958 12.24%
2010 1.309.059 -1.9%
2011 1.662.017 21.24%
2012 3.169.829 47.57%
2013 3.353.342 5.47%
2014 16.072.918 79.14%
2015 12.369.622 -29.94%
2016 7.927.000 -56.04%
2017 12.143.000 34.72%
2018 45.467.000 73.29%
2019 93.011.000 51.12%
2020 234.829.000 60.39%
2021 552.604.000 57.51%
2022 450.229.000 -22.74%
2023 411.152.000 -9.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioLife Solutions, Inc. Liabilities
Year Liabilities Growth
1989 400.000
1990 200.000 -100%
1991 100.000 -100%
1992 1.000.000 90%
1993 2.800.000 64.29%
1994 3.800.000 26.32%
1995 4.420.978 14.05%
1996 2.050.461 -115.61%
1997 1.418.612 -44.54%
1998 1.295.843 -9.47%
1999 1.340.718 3.35%
2000 360.265 -272.15%
2001 1.465.824 75.42%
2002 868.097 -68.85%
2003 1.607.790 46.01%
2004 220.310 -629.79%
2005 408.624 46.08%
2006 380.342 -7.44%
2007 3.195.808 88.1%
2008 6.341.735 49.61%
2009 9.160.940 30.77%
2010 10.857.971 15.63%
2011 12.842.503 15.45%
2012 15.655.852 17.97%
2013 16.624.863 5.83%
2014 2.136.601 -678.1%
2015 2.510.251 14.88%
2016 4.761.000 47.27%
2017 2.051.000 -132.13%
2018 2.319.000 11.56%
2019 9.985.000 76.78%
2020 29.583.000 66.25%
2021 71.853.000 58.83%
2022 86.041.000 16.49%
2023 79.135.000 -8.73%

BioLife Solutions, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.55
Net Income per Share
-2.35
Price to Earning Ratio
-7.28x
Price To Sales Ratio
4.97x
POCF Ratio
-107.03
PFCF Ratio
-45.8
Price to Book Ratio
2.24
EV to Sales
5.13
EV Over EBITDA
-17.63
EV to Operating CashFlow
-114.25
EV to FreeCashFlow
-47.28
Earnings Yield
-0.14
FreeCashFlow Yield
-0.02
Market Cap
0,77 Bil.
Enterprise Value
0,79 Bil.
Graham Number
20.06
Graham NetNet
0.05

Income Statement Metrics

Net Income per Share
-2.35
Income Quality
0.07
ROE
0.92
Return On Assets
-0.16
Return On Capital Employed
-0.19
Net Income per EBT
1
EBT Per Ebit
0.94
Ebit per Revenue
-0.49
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0.2
Gross Profit Margin
0.32
Operating Profit Margin
-0.49
Pretax Profit Margin
-0.46
Net Profit Margin
-0.46

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.16
Free CashFlow per Share
-0.39
Capex to Operating CashFlow
1.42
Capex to Revenue
-0.06
Capex to Depreciation
-0.75
Return on Invested Capital
-0.17
Return on Tangible Assets
-0.62
Days Sales Outstanding
57.9
Days Payables Outstanding
42.32
Days of Inventory on Hand
153.15
Receivables Turnover
6.3
Payables Turnover
8.62
Inventory Turnover
2.38
Capex per Share
-0.23

Balance Sheet

Cash per Share
0,94
Book Value per Share
7,62
Tangible Book Value per Share
1.96
Shareholders Equity per Share
7.62
Interest Debt per Share
1.05
Debt to Equity
0.13
Debt to Assets
0.11
Net Debt to EBITDA
-0.55
Current Ratio
2.74
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
0.13
Working Capital
0,07 Bil.
Intangibles to Total Assets
0.6
Average Receivables
0,03 Bil.
Average Payables
0,01 Bil.
Average Inventory
41265500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioLife Solutions, Inc. Dividends
Year Dividends Growth

BioLife Solutions, Inc. Profile

About BioLife Solutions, Inc.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

CEO
Mr. Roderick de Greef
Employee
409
Address
3303 Monte Villa Parkway
Bothell, 98021

BioLife Solutions, Inc. Executives & BODs

BioLife Solutions, Inc. Executives & BODs
# Name Age
1 Ms. Karen Foster
Chief Quality & Operations Officer
70
2 Mr. Roderick de Greef
Chief Executive Officer & Chairman
70
3 Mr. Michael P. Rice
Consultant
70
4 Mr. Troy Wichterman
Chief Financial Officer
70
5 Dr. Aby J. Mathew Ph.D.
Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer
70

BioLife Solutions, Inc. Competitors